Key terms
About DVAX
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DVAX news
Apr 01
4:27pm ET
Dynavax Appoints Interim CFO During MacDonald’s Leave
Mar 19
10:09am ET
Dynavax (NASDAQ:DVAX) Offers Potentially Robust Growth at a Rich Valuation
Mar 12
4:26pm ET
Dynavax Secures New Sublease Agreement Amidst Zymergen’s Bankruptcy
Feb 23
9:45am ET
Dynavax’s Strong Financial Outlook and Heplisav-B Market Expansion Prompt ‘Buy’ Rating
Feb 23
9:42am ET
Dynavax price target raised to $29 from $28 at H.C. Wainwright
Feb 23
8:50am ET
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX) and EDAP TMS (EDAP)
Feb 23
12:15am ET
Dynavax Technologies: A Stable Hold Amidst a Catalyst-Deficient Forecast
Feb 22
11:15pm ET
Dynavax’s Strong Financials and Promising Pipeline Secure Buy Rating
Feb 22
4:04pm ET
Dynavax sees 2024 Heplisav-B product revenue $265M-$280M
Feb 22
4:03pm ET
Dynavax reports Q4 EPS 0c, consensus (1c)
Feb 01
9:58am ET
Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls
Feb 01
4:43am ET
Dynavax initiated with a Neutral at Goldman Sachs
Feb 01
2:16am ET
Dynavax Hold Rating: Solid Performance Counterbalanced by Priced-In Prospects
Jan 09
9:10am ET
Analysts Are Bullish on Top Healthcare Stocks: BioLife Solutions (BLFS), Dynavax (DVAX)
Jan 09
6:32am ET
Dynavax’s Strong Growth Prospects and Robust Vaccine Pipeline Merit a Buy Rating
Jan 08
2:05pm ET
Dynavax (DVAX) Receives a Buy from TD Cowen
Jan 08
9:03am ET
Dynavax sees FY23 HEPLISAV-B vaccine net product revenue about $213M
Jan 08
9:02am ET
Dynavax sees Q4 HEPLISAV-B vaccine net product revenue about $51M
No recent press releases are available for DVAX
DVAX Financials
Key terms
Ad Feedback
DVAX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DVAX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range